Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Viruses. 2021 Jun 23;13(7):1205. doi: 10.3390/v13071205.
Adeno-associated virus (AAV) was first characterized as small "defective" contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments for rare monogenic diseases and many more currently in various phases of the pharmaceutical development pipeline. Herein, we summarize rAAV approaches for the treatment of diverse types of cancers and highlight the natural anti-oncogenic effects of wild-type AAV (wtAAV), including interactions with the cellular host machinery, that are of relevance to enhance current treatment strategies for cancer.
腺相关病毒 (AAV) 于 1965 年首次被描述为在猴腺病毒制剂中的小“缺陷”污染颗粒。此后，腺相关病毒的重组平台 (rAAV) 已成为基因治疗应用的主要候选者之一，导致了两种 FDA 批准的用于治疗罕见单基因疾病的治疗方法，以及更多目前处于药物开发管道的各个阶段的治疗方法。本文总结了 rAAV 治疗多种类型癌症的方法，并强调了野生型 AAV (wtAAV) 的天然抗癌作用，包括与细胞宿主机制的相互作用，这些作用与增强当前癌症治疗策略有关。
